Rotondi et al. conducted a case–control study that included 252 adult kidney transplant recipients dichotomising patient groups based on CXCL9 levels (greater or less than 272.1 pg/ml) before transplantation [41]. This evidence concerns the gene CXCL9 and medical procedure.